TREATMENT OF VIRUS-INDUCED ACUTE RESPIRATORY DISTRESS SYNDROME
The invention is directed to a method of treating viral-induced acute respiratory distress syndrome (ARDS) by administering to a subject with the virial induced ARDS multipotent adult progenitor cells (MAPCs), which are non-embryonic stem, non-germ cells that have a broad differentiation potential and extended replication capacity. The virus inducing the ARDS can be a Betacoronavirus, such as, severe acute respiratory syndrome (SARS), Corona Virus or Middle East Respiratory Syndrome (MERS), or severe acute respiratory syndrome Corona Virus 2 (SARS-CoV-2).
1 . A method of treating viral-induced acute respiratory distress syndrome (ARDS) comprising administering to a subject with viral-induced ARDS cells (I) in amounts sufficient, for a time sufficient, and by a route effective to treat the ARDS, wherein said cells (I) are non-embryonic stem, non-germ cells that have undergone at least 10-40 cell doublings in culture and wherein the cells (I) express telomerase and/or oct4, are not transformed, are not tumorigenic and have a normal karyotype.
2 . The method of claim 1 , wherein the cells (I) express telomerase.
3 . The method of either of claim 1 or 2 , wherein the cells (I) can differentiate into at least two of the endodermal, ectodermal and mesodermal cell types.
4 . The method of any of claims 1 - 3 , wherein the cells (I) express oct4.
5 . The method of any of claims 1 - 4 , wherein the cells (I) are human.
6 . The method of any of claims 1 - 5 , wherein the cells (I) are derived from bone marrow.
7 . The method of any of claims 1 - 6 , wherein the cells (I) have undergone 40 cell doublings in culture.
8 . The method of any of claims 1 - 7 , wherein the cells (I) can undergo at least 40 cells doublings in culture.
9 . The method of any of claims 1 - 8 , wherein the cells (I) are allogeneic.
10 . The method of any of claims 1 - 9 , wherein the virus that induced the ARDS is Betacoronavirus.
11 . The method of claim 10 , wherein the Betacoronavirus is selected from the group consisting of severe acute respiratory syndrome (SARS), Corona Virus or Middle East Respiratory Syndrome (MERS), or severe acute respiratory syndrome Corona Virus 2 (SARS-CoV-2).
12 . The method of claim 1 , wherein the virus is selected from a group consisting of influenza, coronavirus including (SARS-CoV, MERS-CoV, SARS-CoV2), herpes simplex virus, cytomegalovirus, rhinoviruses, respiratory syncytial virus, parainfluenza virus, human metapneumovirus, and adenovirus.
13 . The method of any of claims 1 - 12 , wherein the subject is human.
14 . The method of any of claims 1 - 13 , wherein the route of the administration is intravenous.